Drug-induced liver injury: Diagnosis, management and the role of liver transplantation.

IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY
Hepatology Forum Pub Date : 2024-09-11 eCollection Date: 2025-01-01 DOI:10.14744/hf.2024.2024.0003
Nazli Begum Ozturk, Eren Uskudar, Merih Deniz Toruner, Cem Simsek, Ahmet Gurakar
{"title":"Drug-induced liver injury: Diagnosis, management and the role of liver transplantation.","authors":"Nazli Begum Ozturk, Eren Uskudar, Merih Deniz Toruner, Cem Simsek, Ahmet Gurakar","doi":"10.14744/hf.2024.2024.0003","DOIUrl":null,"url":null,"abstract":"<p><p>Drug-induced liver injury (DILI) is caused by various medications or herbals/nutritional supplements resulting in liver test abnormalities or hepatic dysfunction. DILI can be categorized as direct (intrinsic), idiosyncratic, or immune-mediated (indirect), and patterns of injury can be categorized as hepatocellular, cholestatic, or mixed injury. DILI is diagnosed after excluding other causes of liver injury. Cessation of the suspected drug along with supportive care is recommended for most DILI cases. In life-threatening situations, liver transplantation (LT) can be considered; however, the risks with LT and lifelong immunosuppression should be considered. In this paper, we summarize the pathophysiology, diagnosis, medical management, and LT for DILI.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"6 2","pages":"72-76"},"PeriodicalIF":1.2000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999897/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/hf.2024.2024.0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Drug-induced liver injury (DILI) is caused by various medications or herbals/nutritional supplements resulting in liver test abnormalities or hepatic dysfunction. DILI can be categorized as direct (intrinsic), idiosyncratic, or immune-mediated (indirect), and patterns of injury can be categorized as hepatocellular, cholestatic, or mixed injury. DILI is diagnosed after excluding other causes of liver injury. Cessation of the suspected drug along with supportive care is recommended for most DILI cases. In life-threatening situations, liver transplantation (LT) can be considered; however, the risks with LT and lifelong immunosuppression should be considered. In this paper, we summarize the pathophysiology, diagnosis, medical management, and LT for DILI.

药物性肝损伤:诊断、治疗和肝移植的作用。
药物性肝损伤(DILI)是由各种药物或草药/营养补充剂引起的,导致肝脏检查异常或肝功能障碍。DILI可分为直接(内在)、特异性或免疫介导(间接),损伤类型可分为肝细胞性、胆汁淤积性或混合性损伤。DILI是在排除其他肝损伤原因后诊断出来的。对于大多数DILI病例,建议停用疑似药物并给予支持性治疗。在危及生命的情况下,可以考虑肝移植(LT);然而,肝移植和终身免疫抑制的风险应予以考虑。本文就DILI的病理生理、诊断、医疗管理和肝移植进行综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
12.50%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信